United Kingdom approves COVID-19 antiviral pill as a potentially game-changing tool against the pandemic. The treatment is being developed jointly by Merck & Co Inc. and Ridgeback Biotherapeutics. British regulators have approved Molnupiravir for use in people with mild to moderate COVID-19. The antiviral works by reducing a virus’ ability to replicate, thereby slowing the disease down.
Clinical trial data suggests that the drug is most effective when taken during the early stage of infection. According to the MHRA, it should be used within five days of the onset of symptoms.